Earlier this week, Life Biosciences, a biotech company focused on reversing age-related diseases, announced that it had dosed its first volunteer. A person with glaucoma has had an experimental treatment injected straight into their eyeball. The idea is to try to treat the disease—which can cause vision loss—by regenerating healthy nerves in the eye. But…
The viral personal AI assistant formerly known as Clawdbot has a new shell — again. After briefly rebranding as Moltbot, it has now picked OpenClaw as its new name.
To unpack what SpaceX’s IPO chatter means, how private liquidity works before a debut, and what investors are looking for in today’s pre-IPO giants, we spoke with Greg Martin, managing director at Rainmaker Securities, a broker-dealer specializing in secondary share transactions for late-stage private companies.